-$0.10 EPS Expected for Vistagen Therapeutics Inc (NASDAQ:VTGN) This Quarter

Brokerages expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.15) per share in the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The business is scheduled to announce its next earnings results on Tuesday, June 23rd.

On average, analysts expect that Vistagen Therapeutics will report full-year earnings of ($0.52) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will report earnings of ($0.44) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Vistagen Therapeutics.

Several research firms recently commented on VTGN. Maxim Group reaffirmed a “buy” rating and set a $1.00 price objective on shares of Vistagen Therapeutics in a research report on Friday. Zacks Investment Research raised Vistagen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, ValuEngine raised Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $0.85.

An institutional investor recently bought a new position in Vistagen Therapeutics stock. Advisor Group Holdings Inc. acquired a new position in Vistagen Therapeutics Inc (NASDAQ:VTGN) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 171,414 shares of the company’s stock, valued at approximately $75,000. Advisor Group Holdings Inc. owned 0.35% of Vistagen Therapeutics as of its most recent SEC filing. 4.83% of the stock is currently owned by institutional investors.

Shares of Vistagen Therapeutics stock traded down $0.02 during trading on Friday, hitting $0.52. 829,537 shares of the company’s stock traded hands, compared to its average volume of 1,274,114. Vistagen Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.49. The stock has a market capitalization of $26.77 million, a P/E ratio of -0.89 and a beta of 0.31. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.55.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: What is a resistance level?

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.